Exporting Supplements Made in the USA to Australia: TGA Compliance Explained

Australia is one of the most attractive export markets for U.S.-manufactured supplement brands. Consumers there are highly engaged with complementary medicine, regulatory standards are clearly defined and well-enforced, and the market rewards quality credentials in ways that directly benefit brands manufactured under U.S. cGMP standards. But exporting dietary supplements from the United States to Australia is not a matter of shipping product and attaching a translated label. The Therapeutic Goods Administration (TGA) operates one of the most structured complementary medicine regulatory frameworks in the world, and understanding its requirements before you begin the process will save significant time and cost. This guide covers everything U.S. supplement brands and their manufacturing partners need to know.

The Australian Complementary Medicine Market

Australia’s complementary medicine sector — encompassing vitamins, minerals, herbal preparations, and other complementary healthcare products — is a substantial and growing market. The sector generates approximately AUD $6 billion annually, with consistent year-on-year growth driven by an aging population, rising preventive health awareness, and strong consumer trust in complementary medicine products.

Australia’s proximity to Southeast Asia and its significant Chinese-Australian population make it a strategic gateway market for brands also targeting the broader Asia-Pacific region. Products that achieve TGA compliance and establish Australian market presence are frequently well-positioned to expand into adjacent markets in the region.

The TGA Regulatory Framework

The Therapeutic Goods Administration is an Australian Government agency within the Department of Health responsible for regulating therapeutic goods — including prescription medicines, medical devices, and complementary medicines — under the Therapeutic Goods Act 1989. Unlike the U.S. FDA’s framework for dietary supplements, which requires minimal pre-market interaction for most products, the TGA requires that therapeutic goods be included in the Australian Register of Therapeutic Goods (ARTG) before they can be legally supplied in Australia.

This means every supplement product you intend to sell in Australia must be assessed and registered or listed with the TGA before a single unit is imported or sold.

Listed vs. Registered Medicines: The Core Distinction

The TGA divides complementary medicines into two categories based on their risk profile, which determines the regulatory pathway:

Feature	Listed Medicine (ARTG Listed)	Registered Medicine (ARTG Registered)
Risk level	Low risk	Higher risk
TGA review	Self-assessed by sponsor; TGA audits post-listing	Full TGA evaluation of safety, quality, and efficacy
Permitted ingredients	Must use only ingredients from the permitted ingredients list	Can include ingredients not on the permitted list
Permitted indications	Standard indications only from TGA’s permitted list	Custom indications supported by clinical evidence
Timeline	Days to weeks (self-assessed online)	12–18+ months (full evaluation process)
Cost	Lower — AUD $900–$1,200 application fee	Higher — AUD $50,000–$200,000+ evaluation fees
Label identifier	“AUST L” number on label	“AUST R” number on label
Suitable for most supplements	Yes — vitamins, minerals, herbal extracts	Only if making therapeutic efficacy claims requiring evidence

The vast majority of U.S. dietary supplement brands exporting to Australia will pursue the Listed medicine pathway. If your product contains only permitted ingredients and your label claims fall within the TGA’s standard permitted indications, listing is the appropriate and significantly faster route.

The ARTG Listing Process for Complementary Medicines

Listing a complementary medicine in the ARTG is a sponsor-managed process conducted through the TGA’s online Business Services portal. The sponsor — the Australian entity legally responsible for the product — self-certifies that the product meets all legislative requirements before submitting the listing application.

Step-by-Step Overview

1. Confirm ingredient compliance: Every active and excipient ingredient must appear on the TGA’s Permitted Ingredients list under the Therapeutic Goods (Permissible Ingredients) Determination. Any ingredient not on this list requires a separate application process before listing can proceed.
2. Select permitted indications: Label claims must be drawn from the TGA’s Standard Indications list. Claims outside this list — including any reference to disease treatment, diagnosis, or cure — require the Registered medicine pathway with supporting clinical evidence.
3. Confirm GMP compliance of the manufacturer: The overseas manufacturer (your U.S. CMO) must hold evidence of GMP compliance acceptable to the TGA. This is a critical step discussed in detail below.
4. Prepare product information and label: Draft labeling must comply with the Therapeutic Goods Order 92 (TGO 92) labeling standard for complementary medicines.
5. Engage an Australian sponsor: The listing must be made by or on behalf of an Australian-resident sponsor — an individual or company with an Australian Business Number (ABN). U.S. brands without an Australian entity must engage a local sponsor or distributor.
6. Submit the ARTG listing application: The sponsor submits via TGA Business Services, self-certifying compliance with all requirements. The TGA issues the AUST L number typically within days to weeks of a complete submission.
7. Post-market compliance: Listed products are subject to TGA compliance audits. The sponsor must retain all evidence of compliance for five years following supply.

Permitted Ingredients: What’s Allowed in Listed Medicines

The TGA’s Permitted Ingredients Determination specifies which substances can be used in listed complementary medicines and at what maximum doses. This list is extensive — covering most common vitamins, minerals, amino acids, and herbal extracts — but it is not identical to what is permitted in U.S. dietary supplements under DSHEA.

Key points for U.S. brands to verify before committing to the Australian market:

• Check each active ingredient against the Permitted Ingredients Determination, including the permitted form (e.g., magnesium citrate is listed; a novel form may not be)
• Verify that your label dose falls within the TGA’s permitted maximum dose for each ingredient
• Some botanical extracts permitted in the U.S. require specific extract ratio or standardization specifications under TGA requirements
• Novel ingredients or those not yet evaluated by the TGA may require a separate permitted ingredient application, adding 6–12 months to the process

GMP Evidence Requirements for Overseas Manufacturers

This is the step that most directly affects U.S. supplement brands and their manufacturing partners, and it is where TGA compliance intersects with your CMO selection.

Australian law requires that all therapeutic goods supplied in Australia — including Listed complementary medicines — are manufactured under GMP standards acceptable to the TGA. For overseas manufacturers, this means providing GMP Evidence that satisfies the TGA’s requirements under the Therapeutic Goods Act.

Acceptable Forms of GMP Evidence for U.S. Manufacturers

• TGA GMP Clearance: The TGA can conduct its own inspection of a foreign manufacturing facility or accept a GMP certificate from a recognized overseas regulator. A U.S. manufacturer inspected and cleared by the TGA receives a TGA GMP Clearance valid for three years.
• PIC/S GMP Certificate: The Pharmaceutical Inspection Co-operation Scheme (PIC/S) is an international framework of mutual recognition among regulatory authorities. The U.S. FDA is a PIC/S member. A manufacturing facility that has been inspected by the FDA under PIC/S-equivalent standards may be able to use FDA inspection records as the basis for TGA GMP clearance, subject to TGA assessment.
• Certificate of GMP Compliance from a recognized authority: GMP certificates issued by regulatory authorities in ICH member countries or PIC/S members are generally acceptable to the TGA as supporting evidence.

The practical implication: a U.S. supplement CMO operating under FDA-inspected cGMP standards is well-positioned to obtain TGA GMP clearance. The process requires a formal application to the TGA, submission of recent inspection reports, and may involve a TGA desktop review or on-site inspection. Timelines vary from several months to over a year depending on TGA workload and the completeness of documentation.

Australian Labeling Requirements

Labels for Listed complementary medicines sold in Australia must comply with Therapeutic Goods Order 92 (TGO 92). Key requirements differ from U.S. labeling standards in several important ways:

• AUST L number: The TGA-issued listing number must appear on the label
• Sponsor details: The Australian sponsor’s name and address must appear — not just the U.S. manufacturer
• Ingredient naming: Ingredients must be named using TGA-specified terminology, which may differ from common U.S. label conventions
• Warning statements: TGO 92 specifies mandatory warning statements for certain ingredients (e.g., specific warnings for products containing kava, valerian at high doses, or products not suitable for children)
• Indication wording: Claims must use the exact wording from the TGA’s Standard Indications list — paraphrasing is not permitted
• No Supplement Facts panel: Australian labeling uses a different declaration format than the U.S. Supplement Facts panel

Most U.S. brands create Australia-specific label versions rather than attempting to adapt their U.S. label to meet TGO 92 requirements. Budget for label redesign as a line item in your Australian market entry cost.

Timeline and Cost Summary

• Ingredient compliance review: 2–4 weeks (internal or with regulatory consultant)
• TGA GMP Clearance for U.S. manufacturer: 3–12 months (first-time applications)
• Australian sponsor engagement: 2–6 weeks to identify and contract
• Label development to TGO 92 standard: 4–8 weeks
• ARTG listing submission and approval: Days to weeks once all documentation is complete
• Total market entry timeline: 6–18 months depending primarily on GMP clearance processing time
• Application fees: Approximately AUD $900–$1,200 per Listed product; regulatory consultant fees typically AUD $5,000–$20,000 depending on complexity

How Atrium Scientific Group Supports Australian Market Entry

Atrium Scientific Group’s USA-based cGMP manufacturing facility is structured to support the documentation requirements associated with international regulatory submissions, including TGA GMP clearance applications. Our quality team can provide the manufacturing records, SOPs, batch documentation, and audit support that Australian regulatory counsel requires to complete a TGA GMP clearance package. Contact our team to discuss your Australian market entry plans and how our manufacturing documentation can support your TGA application.

Frequently Asked Questions

Do I need a separate ARTG listing for each product I want to sell in Australia?

Yes. Each distinct product formulation requires its own ARTG listing with a unique AUST L number. Different pack sizes of the same formulation may share a listing in some circumstances, but different formulations — different active ingredients, different doses, or different dosage forms — each require individual listings.

Can I sell my U.S.-labeled product in Australia while waiting for TGA listing?

No. Therapeutic goods cannot be legally supplied in Australia without ARTG inclusion. Supplying unlisted therapeutic goods is a criminal offense under the Therapeutic Goods Act. Do not commence sales, distribution, or commercial importation until your ARTG listing is confirmed and your label displays the AUST L number.

Does my U.S. CMO’s NSF or UL cGMP certification satisfy TGA GMP requirements?

Third-party cGMP certifications from NSF, UL, or NPA support the GMP evidence package but are not themselves sufficient to satisfy TGA GMP requirements without TGA assessment. The TGA must formally evaluate and clear the overseas manufacturer. These certifications strengthen the application and may expedite TGA review, but the clearance must be formally granted by the TGA.

What is an Australian sponsor and do I need one?

An Australian sponsor is the individual or company legally responsible for the therapeutic goods in Australia — they hold the ARTG listing, are responsible for post-market compliance, and must have an Australian Business Number. U.S. brands without an Australian entity must engage an Australian distributor, regulatory affairs firm, or dedicated sponsor service to hold the listing on their behalf. This is a standard arrangement for international brands entering the Australian market.

Are there any U.S. supplement ingredients that are not permitted in Australian Listed medicines?

Yes. Some ingredients common in U.S. dietary supplements are not on the TGA’s Permitted Ingredients list, are restricted to lower doses than U.S. labels typically use, or require specific forms that differ from U.S. supply chains. Kava is subject to strict dose limitations and mandatory warnings. Certain stimulant botanicals, high-dose melatonin, and some novel ingredients require additional TGA assessment. A thorough ingredient-by-ingredient review against the Permitted Ingredients Determination is essential before committing to the Australian market.

Conclusion

Australia represents a genuine commercial opportunity for U.S. supplement brands willing to navigate its regulatory framework — and that framework, while thorough, is predictable and well-documented. The TGA’s requirements reward quality manufacturing, transparent ingredient sourcing, and careful label compliance: exactly the standards that U.S. cGMP-certified manufacturers are already built to meet. Starting the GMP clearance process early — before you need the products in market — is the single most effective way to compress your Australian entry timeline. Atrium Scientific Group’s manufacturing and quality documentation infrastructure is designed to support exactly this process. Contact us to discuss your international expansion plans.